Rua Bioscience Past Earnings Performance
Past criteria checks 0/6
Rua Bioscience's earnings have been declining at an average annual rate of -38.2%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 25.2% per year.
Key information
-38.2%
Earnings growth rate
-23.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.6% |
| Revenue growth rate | 25.2% |
| Return on equity | -202.7% |
| Net Margin | -4,336.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
May 13
Companies Like Rua Bioscience (NZSE:RUA) Are In A Position To Invest In Growth
Dec 17Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Jul 02Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Mar 09Revenue & Expenses Breakdown
How Rua Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -14 | 0 | 1 |
| 31 Mar 24 | 0 | -16 | 0 | 1 |
| 31 Dec 23 | 1 | -18 | 0 | 1 |
| 30 Sep 23 | 1 | -12 | 0 | 1 |
| 30 Jun 23 | 1 | -6 | 0 | 2 |
| 31 Mar 23 | 1 | -6 | 0 | 2 |
| 31 Dec 22 | 1 | -5 | 0 | 2 |
| 30 Sep 22 | 1 | -7 | 0 | 3 |
| 30 Jun 22 | 1 | -9 | 0 | 3 |
| 31 Mar 22 | 1 | -7 | 0 | 3 |
| 31 Dec 21 | 1 | -5 | 0 | 3 |
| 30 Sep 21 | 1 | -4 | 0 | 2 |
| 30 Jun 21 | 0 | -4 | 0 | 2 |
| 31 Mar 21 | 0 | -4 | 0 | 2 |
| 31 Dec 20 | 0 | -4 | 0 | 1 |
| 30 Sep 20 | 0 | -3 | 0 | 1 |
| 30 Jun 20 | 0 | -3 | 0 | 1 |
| 30 Jun 19 | 0 | -2 | 0 | 1 |
Quality Earnings: RUA is currently unprofitable.
Growing Profit Margin: RUA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RUA is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.
Accelerating Growth: Unable to compare RUA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: RUA has a negative Return on Equity (-202.74%), as it is currently unprofitable.